ArticlePsychopharmacology2026
The impact of anti-craving medication on cue reactivity and abstinence in patients undergoing alcohol detoxification: some preliminary evidence from a retrospective event-related potentials study.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationaleWhile medications such as acamprosate, baclofen, or naltrexone have shown promising effects in the treatment of alcohol use disorder (AUD), meta-analyses have yielded conflicting findings regarding their efficacy. This retrospective study examined whether alcohol cue reactivity and its neural correlates could serve as protective factors against relapse in AUD inpatients receiving pharmacological treatment during a three-week detoxification program.
methodFifty-eight inpatients diagnosed with AUD undergoing a three-weeks detoxification program were selected. These patients received either acamprosate (n = 21), naltrexone (n = 21), or baclofen (n = 16) during their stay. They completed an event-related potential cue-reactivity task at the beginning (T0) and end (T1) of the program. Follow-up data on relapse were collected up to two months post- discharge.
resultsThe Log-Rank (Mantel-Cox) test ([Formula: see text] (2) = 5.84; p =.059) revealed a marginally significant difference in survival distributions between medications. A significant difference emerged between baclofen and acamprosate groups ([Formula: see text] (1) = 4.73; p =.030), with slower return to alcohol use in the baclofen group. No other significant difference emerged between the acamprosate and naltrexone groups or between the naltrexone and baclofen groups (p >.05). Only the baclofen group showed a significant reduction in oddball P3 amplitude between T0 and T1 (p =.002), suggesting decreased neural cue reactivity.
conclusionA reduction in neural cue reactivity, observed exclusively in the baclofen group, may act as a protective factor against early relapse in AUD. However, this study was underpowered, and findings should be interpreted cautiously until confirmed in larger prospective investigations.
Indexed as
Identifiers
40681661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.